Home  »  Companies   »  Would I Ever Invest In AbCellera Biologics Inc. (N...

Would I Ever Invest In AbCellera Biologics Inc. (NASDAQ: ABCL) At Any Point In Time?

AbCellera Biologics Inc. (NASDAQ:ABCL) price is hovering lower on Tuesday, July 05, dropping -0.89% below its previous close.

A look at today’s price movement shows that the recent level at last check reads $10.64, with intraday deals fluctuating between $10.43 and $10.92. The company’s P/E ratio in the trailing 12-month period read 16.27. Taking into account the 52-week price action we note that the stock hit a 52-week high of $22.63 and 52-week low of $5.42. The stock added 36.41% on its value in the past month.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

AbCellera Biologics Inc., which has a market valuation of $3.03 billion, is expected to release its quarterly earnings report Mar 28, 2022 – Apr 01, 2022. Analysts tracking ABCL have forecast the quarterly EPS to grow by 0.05 per share this quarter, while the same analysts predict the annual EPS to hit $0.31 for the year 2022 and up to -$0.41 for 2023. In this case, analysts estimate an annual EPS growth of -35.40% for the year and -232.30% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $74.15 million, with the likely lows of $9.53 million and highs of $154.11 million. The average estimate suggests sales growth for the quarter will likely rise by 3.70% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $356.88 million for the company’s annual revenue in 2022. Per this projection, the revenue is forecast to grow -4.90% below that which the company brought in 2022.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give ABCL a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as Hold.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 8 analysts have assigned ABCL a recommendation rating as follows: 0 rate it as a Hold; 8 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the AbCellera Biologics Inc. (ABCL) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

If we dive deeper into the stock’s performance we see the positive picture represented by the PEG ratio, currently standing at 1.63. The overview shows that ABCL’s price is at present 13.02% off the SMA20 and 26.97% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 66.82, with weekly volatility standing at 6.46%. The indicator jumps to 6.96% when calculated based on the past 30 days. AbCellera Biologics Inc. (NASDAQ:ABCL)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 0.63. Considering analysts have assigned the stock a price target range of $14.00-$43.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $30.00. Based on this estimate, we see that today’s price at last check is roughly -32.7% off the estimated low and -307.58% off the forecast high. Investors will no doubt be excited to see the share price fall to $31.00, which is the median consensus price, and at that level ABCL would be -193.84% from recent price.

Turning out attention to how the AbCellera Biologics Inc. stock has performed in comparison to its peers in the industry, here’s what we find: ABCL’s stock is -0.89% on the day and -48.25% in the past 12 months, while AbbVie Inc. (ABBV) traded -1.96% in the latest session and is positioned 34.61% up on its price 12 months ago. Another comparison is with Genmab A/S (GMAB) whose stock price is down -0.55% in the current trading session, and has flourished -19.54% over the past year. Also, Charles River Laboratories International Inc. (CRL) is currently showing down trend of -0.30% while its price kept floating at -41.28% over the past year. As for AbCellera Biologics Inc., the P/E ratio stands at 16.27 lower than that of AbbVie Inc.’s at 22.06 and Genmab A/S’s 65.94. Elsewhere in the market, the S&P 500 Index has stumbled -1.88% in today’s early trading, with the Dow Jones Industrial also seeing a negative session so far with -2.20%.

An analysis of the AbCellera Biologics Inc. (NASDAQ:ABCL) stock in terms of its daily trading volume indicates that the 3-month average is 2.58 million. However, this figure increases on the past 10-day timeline to an average of 5.57 million.

Current records show that the company has 283.89M in outstanding shares. The insiders’ percentage holdings are 20.40% of outstanding shares while the percentage share held by institutions stands at 40.30%. The stats also highlight that short interest as of Apr 28, 2022, stood at 11.72 million shares, which puts the short ratio at the time at 9.03. From this we can glean that short interest is 4.12% of company’s current outstanding shares. Notably, we see that shares short in April fall slightly given the previous month’s figure stood at 12.03 million. But the -25.59% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]